A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.
Saved in:
| Title: | A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. |
|---|---|
| Authors: | Hamm C; University of Windsor, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Western University, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA. caroline.hamm@wrh.on.ca.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca., Fifield BA; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada., Kay A; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada., Kulkarni S; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada., Gupta R; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada., Mathews J; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada., Ferraiuolo RM; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA., Al-Wahsh H; University of Calgary, Calgary, AB, Canada., Mailloux E; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada., Hussein A; University of Windsor, Windsor, ON, N9B 3P4, Canada., Porter LA; University of Windsor, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca. |
| Source: | Medical oncology (Northwood, London, England) [Med Oncol] 2022 Feb 01; Vol. 39 (4), pp. 49. Date of Electronic Publication: 2022 Feb 01. |
| Publication Type: | Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35103812 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hamm+C%22">Hamm C</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Western University, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA. caroline.hamm@wrh.on.ca.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.<br /><searchLink fieldCode="AU" term="%22Fifield+BA%22">Fifield BA</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Kay+A%22">Kay A</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Kulkarni+S%22">Kulkarni S</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Gupta+R%22">Gupta R</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Mathews+J%22">Mathews J</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Ferraiuolo+RM%22">Ferraiuolo RM</searchLink>; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA.<br /><searchLink fieldCode="AU" term="%22Al-Wahsh+H%22">Al-Wahsh H</searchLink>; University of Calgary, Calgary, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Mailloux+E%22">Mailloux E</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Hussein+A%22">Hussein A</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada.<br /><searchLink fieldCode="AU" term="%22Porter+LA%22">Porter LA</searchLink>; University of Windsor, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229435512%22">Medical oncology (Northwood, London, England)</searchLink> [Med Oncol] 2022 Feb 01; Vol. 39 (4), pp. 49. <i>Date of Electronic Publication: </i>2022 Feb 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9435512 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1559-131X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213570560%22">13570560 </searchLink><i>NLM ISO Abbreviation: </i>Med Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35103812 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12032-021-01637-0 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 49 Titles: – TitleFull: A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hamm C – PersonEntity: Name: NameFull: Fifield BA – PersonEntity: Name: NameFull: Kay A – PersonEntity: Name: NameFull: Kulkarni S – PersonEntity: Name: NameFull: Gupta R – PersonEntity: Name: NameFull: Mathews J – PersonEntity: Name: NameFull: Ferraiuolo RM – PersonEntity: Name: NameFull: Al-Wahsh H – PersonEntity: Name: NameFull: Mailloux E – PersonEntity: Name: NameFull: Hussein A – PersonEntity: Name: NameFull: Porter LA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2022 Feb 01 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1559-131X Numbering: – Type: volume Value: 39 – Type: issue Value: 4 Titles: – TitleFull: Medical oncology (Northwood, London, England) Type: main |
| ResultId | 1 |
